- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
- Interventions
- TARA-002, Investigator's Choice of Intravesical Chemotherapy
- Drug
- Lead sponsor
- Protara Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 9
- States / cities
- Queen Creek, Arizona • Little Rock, Arkansas • Bakersfield, California + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–58
of 58
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-Muscle Invasive Bladder Cancer (NMIBC)
- Interventions
- Bacillus Calmette-Guérin (BCG), Gemcitabine
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 8
- States / cities
- Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
- Conditions
- High-Risk Non-Muscle-Invasive Bladder Cancer
- Interventions
- Cretostimogene Grenadenorepvec
- Drug
- Lead sponsor
- CG Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 79
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 70 more
- Conditions
- Invasive Bladder Cancer, Bladder Cancer
- Interventions
- Gemcitabine and fractionated cisplatin (combination treatment)
- Drug
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Providence, Rhode Island
- Conditions
- Urothelial Carcinoma, Non-Invasive Bladder Urothelial Carcinoma
- Interventions
- Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)
- Biological
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Non-muscle-invasive Bladder Cancer
- Interventions
- STM-416
- Drug
- Lead sponsor
- SURGE Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 20
- States / cities
- Mesa, Arizona • Tucson, Arizona • Little Rock, Arkansas + 16 more
- Conditions
- Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
- Interventions
- Intismeran autogene, BCG
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 308 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 20
- States / cities
- Bakersfield, California • Los Alamitos, California • Los Angeles, California + 15 more
- Conditions
- Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer
- Interventions
- EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy)
- Drug
- Lead sponsor
- enGene, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 43 more
- Conditions
- Bladder Cancer
- Interventions
- CG0070
- Biological
- Lead sponsor
- CG Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 17
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 13 more
- Conditions
- Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
- Interventions
- Nadofaragene Firadenovec, Gemcitabine, Docetaxel, Pembrolizumab
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 40
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more